Tislelizumab plus Bevacizumab

Phase 2Monoclonal antibody

HHenan Provincial People's Hospital

Tislelizumab plus Bevacizumab is one of 65 small molecule programs targeting Astrocytoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AstrocytomaActive, not recruiting

OligodendrogliomaActive, not recruiting

GlioblastomaActive, not recruiting

AstrocytomaPhase 2

Active, not recruiting

OligodendrogliomaPhase 2

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

514 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

161 2

Ceenu

AAzurity Pharmaceuticals

Phase 3

22 3

Gleevec

Novartis

Phase 3

2 4

Scemblix

Novartis

Phase 3

1 5

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 6

Lexapro

AbbVie

Phase 3

1 7

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 8

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 10

Droxia

TTheravia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Oligodendroglioma

NCT05512351

Phase 2Not yet recruiting

Glioblastoma

NCT05540275

Q4 2027

Phase 2Not yet recruiting

Glioblastoma

NCT05502991

Phase 2Not yet recruiting

Astrocytoma

NCT05518994

Clinical

Trials by Indication[1]

Glioblastoma2 trials

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Not yet recruiting·HHenan Provincial People's Hospital·Phase 2·NCT05540275·30 enrolled

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Not yet recruiting·HHenan Provincial People's Hospital·Phase 2·NCT05502991·60 enrolled

Oligodendroglioma1 trial

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Recruiting·HHenan Provincial People's Hospital·Phase 2·NCT05512351·80 enrolled

Astrocytoma1 trial

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Not yet recruiting·HHenan Provincial People's Hospital·Phase 2·NCT05518994·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tislelizumab plus Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tislelizumab plus Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tislelizumab plus Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: HHenan Provincial People's Hospital

Tislelizumab plus Bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Glioblastoma2 trials

Oligodendroglioma1 trial

Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News